CAPR Stock: Capricor Therapeutics, Inc. Stock Price, Analysis & Insights
Get live capr stock price $30.90, comprehensive Capricor Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time capr stock data and investment insights.
Loading chart...
Company Overview
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Company Information
- CEO
- Linda Marbán
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 160
Contact Information
- Website
- https://www.capricor.com
- Address
- 10865 Road to the Cure
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.59) may provide portfolio stability
Business Model & Strategy
Capricor Therapeutics, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Linda Marbán, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Capricor Therapeutics, Inc. competes in the Biotechnology within the broader Healthcare. With 1.4 billion in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Capricor Therapeutics, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Capricor Therapeutics, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Capricor Therapeutics, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Capricor Therapeutics, Inc.
- ⚠Investors should consider how Capricor Therapeutics, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
1.41B
P/E Ratio
-17.66
Beta
0.59
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 1.41B market capitalization
- Trading Volume: 43.87M shares traded today
- Price Range: 52-week range of $4.30 - $40.37
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. (CAPR) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 1.41B, the company represents a significant player in its market. The stock is currently trading at $30.90 with a positivedaily change of 385.85%.
The company's 160 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -17.66, beta of 0.59, and 52-week price range from $4.30 to $40.37when evaluating investment opportunities.
Why Invest in Capricor Therapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Linda Marbán
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.